Kleresca® employs industrial postdoc researcher to investigate impact of fluorescent light energy (FLE) on human immune system

Ballerup, Denmark, November 2018. Kleresca®, a medical technology company focused on the development and commercialisation of a unique biophotonic technology in dermatology, has strengthened its research activities by employing an industrial postdoc to investigate the impact of FLE on skin macrophages.

Dr. Maiken Mellergaard, PhD in Immunology and Infectious Diseases, has been employed as industrial postdoc by Kleresca® in collaboration with University of Copenhagen (UCPH) to investigate how FLE impacts the macrophages in the human immune system.

According to the Kleresca® General Manager, an increase of the current knowledge of the FLE technology is a prerequisite for dispersing the technology into more therapeutic areas for the benefit of patients worldwide.

“We are very excited to welcome Dr. Mellergaard to the team. She will help us understand our technology in more detail in relation to the immune system. This will enable us to develop more treatments for inflammatory skin diseases going forward”, says Mr. Mikkel Schoedt, General Manager of Kleresca®.

Co-financed by The Innovation Fund Denmark, Dr. Mellergaard is based at the UCPH and reports to the faculty professor as well as to the Director of Clinical and Scientific Affairs in Kleresca®.

This constellation is intended to provide an unbiased scientific foundation for the investigation. It also it allows Kleresca® access to research facilities and knowledge within different areas of highly relevant research.

Professor at the UCPH Faculty of Health and Medical Sciences, Prof. Dr. Søren Skov says:

“This research project focusing on FLE in dermatology opens up for whole new perspectives within immunology and we are excited to be part of it”.

Prof. Dr. Søren Skov is the scientific mentor for the postdoc during the entire research period of two years.

Nadia Vega Vasiljev
Global PR and Communication
nvv@kleresca.com

 

At Kleresca®, we aspire to change the fundamentals of dermatology. Our innovative biophotonic technology represents a unique mode of action that allows us to create a new gold standard within the industry for the benefit of patients worldwide. The Kleresca® biophotonic platform offers non-invasive treatments for both therapeutic and aesthetic conditions using fluorescent light energy (FLE) to stimulate the skin’s own biological processes and repair mechanisms through photobiomodulation (PBM). Demonstrating high safety and efficacy, our technology triggers documented skin repairing benefits for a number of diseases and conditions. The company is headquartered in Dublin, Ireland, and builds on the scientific heritage from LEO Pharma and KLOX Technologies. Kleresca® is currently developing ten (10) markets including Australia, Italy, Spain, France, Switzerland, Germany, Belgium, Denmark, Norway and UK. Kleresca® is also registered as FB Dermatology.

Tags:

About Us

Klox Technologies Inc. is a private biomedical technology innovator, advancing the development and commercialization of its flagship fluorescent light energy generating technology within regenerative medicine. Klox has developed franchises in wound care, dermatology, animal health and oral health.

Subscribe

Media

Media

Documents & Links

Quick facts

Kleresca® employs Dr. Maiken Mellergaard, PhD in Immunology and Infectious Diseases, in an industrial postdoc position to investigate how FLE impacts the macrophages in the human immune system.
Tweet this

Quotes

This research project focusing on FLE in dermatology opens up for whole new perspectives within immunology and we are excited to be part of it.
Prof. Dr. Søren Skov, University of Copenhagen